Literature DB >> 3552588

Aspirin and related derivatives of salicylic acid.

S P Clissold.   

Abstract

After almost 90 years of clinical use, aspirin remains one of the world's most extensively used 'over-the-counter' drugs, and it is still recognised as the standard analgesic/antipyretic/anti-inflammatory agent by which newer drugs are assessed. However, its pre-eminent position as the analgesic of choice for mild to moderate pain has been seriously challenged with the introduction of many 'new' non-steroidal non-narcotic analgesic drugs. Indeed, there is convincing scientific evidence that many of the 'newer' non-steroidal drugs such as diflunisal, ibuprofen, flurbiprofen etc. are significantly superior analgesics and, in many cases, have a longer duration of action. In recent years the salicylates, aspirin in particular, have been the focus of much attention regarding their side effect profiles. At usual dosages for relief of pain and during occasional use, aspirin is well tolerated by the vast majority of patients. Adverse reactions, of which there is a wide spectrum, most frequently accompany anti-inflammatory doses of aspirin, or may be the result of accidental overdosing (particularly in children and the elderly)--probably a reflection of the lay population's acceptability of aspirin's presumed safety. As with other non-steroidal analgesic drugs, gastrointestinal complaints are the most commonly reported side effects. The existence of many shared clinical, adverse and toxic effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is thought to be accounted for by a common mechanism--inhibition of the ubiquitous cyclo-oxygenase enzyme. Thus, suppression of prostaglandin biosynthesis is widely considered to explain the common properties of NSAIDS, although further research is still necessary to clarify some inconsistencies and to complete our understanding of the processes involved. Aspirin and salicylates have been reported to have a wide range of drug interactions but only relatively few seem to be clinically important. Many of the interactions are pharmacokinetic in nature. Drugs considered to produce the most significant interactions with salicylates include anticoagulants and thrombolytic agents, uricosuric agents, corticosteroids, methotrexate and sulphonylurea hypoglycaemic agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3552588     DOI: 10.2165/00003495-198600324-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  57 in total

1.  Analgesic drugs.

Authors:  L LASAGNA
Journal:  Am J Med Sci       Date:  1961-11       Impact factor: 2.378

2.  Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

Authors:  M Rowland; S Riegelman; P A Harris; S D Sholkoff
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

3.  Salicylate accumulation kinetics in man.

Authors:  G Levy; T Tsuchiya
Journal:  N Engl J Med       Date:  1972-08-31       Impact factor: 91.245

4.  Teratogenic drugs--R.C.G.P. survey.

Authors:  D L Crombie; R J Pinsent; B C Slater; D Fleming; K W Cross
Journal:  Br Med J       Date:  1970-10-17

5.  A 12-hour evaluation of the analgesic efficacy of diflunisal, aspirin, and placebo in postoperative dental pain.

Authors:  J A Forbes; J P Calderazzo; M W Bowser; V M Foor; R W Shackleford; W T Beaver
Journal:  J Clin Pharmacol       Date:  1982 Feb-Mar       Impact factor: 3.126

6.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

7.  Aspirin and congenital malformations.

Authors:  D Slone; V Siskind; O P Heinonen; R R Monson; D W Kaufman; S Shapiro
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

8.  Antipyretic analgesics and the allergic patient.

Authors:  A Szczeklik
Journal:  Am J Med       Date:  1983-11-14       Impact factor: 4.965

9.  Clinical pharmacokinetics of salicylates: a re-assessment.

Authors:  G Levy
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Toxicity of salicylates.

Authors:  A T Proudfoot
Journal:  Am J Med       Date:  1983-11-14       Impact factor: 4.965

View more
  8 in total

1.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  [Not Available].

Authors:  E Hackenthal
Journal:  Schmerz       Date:  1990-09       Impact factor: 1.107

3.  Profiling of arachidonic acid metabolites in rabbit platelets by radio gas chromatography.

Authors:  K Akira; T Nakamura; Y Shinohara; S Baba
Journal:  Lipids       Date:  1993-04       Impact factor: 1.880

4.  [Drug therapy for tumor pain I. Properties of non-opioids and opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

Review 5.  Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children.

Authors:  P D Walson; M E Mortensen
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 6.  Paracetamol: a focus for the general pediatrician.

Authors:  Pierluigi Marzuillo; Stefano Guarino; Egidio Barbi
Journal:  Eur J Pediatr       Date:  2013-12-28       Impact factor: 3.183

7.  Interaction of acupuncture and electroacupuncture on the pharmacokinetics of aspirin and the effect of brain blood flow in rats.

Authors:  Ming-Tsang Wu; Lee-Hsin Shaw; Yu-Tse Wu; Tung-Hu Tsai
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-25       Impact factor: 2.629

8.  Plant chemical genetics reveals colistin sulphate as a SA and NPR1-independent PR1 inducer functioning via a p38-like kinase pathway.

Authors:  Vivek Halder; Mohamed N S Suliman; Farnusch Kaschani; Markus Kaiser
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.